Pancreatic Cancer Research

ResearcherChang Gung UniversityActive in the last 2 years

Wen‐Chi Chou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0361-4548; OpenAlex author ID A5027932918. Sources: OpenAlex.

Their work

Papers
31 (first author 2, last author 18)
Trials
0
Grants
0
Labs led
1
Collaborators
57
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: 2 papers · 2019: 6 papers · 2020: 2 papers · 2021: 2 papers · 2022: 5 papers · 2023: 1 paper · 2024: 2 papers · 2025: 6 papers · 2026: 4 papers

Papers 31

  1. Third-line platinum-based chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.jfma.2026.01.057↗
  2. Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort. Co-author DOI 10.1016/j.jfma.2026.04.039↗
  3. Reply to comment on" Third-line platinum-based chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma". First author DOI 10.1016/j.jfma.2026.04.043↗
  4. Response to Comment on "Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort… Co-author DOI 10.1016/j.jfma.2026.05.008↗
  5. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer. Co-author DOI 10.1016/j.esmoop.2025.105826↗
  6. Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine-nab-paclitaxel failure: a propensity score… Co-author DOI 10.1016/j.esmoop.2025.105874↗
  7. The efficacy and safety profile of third-line treatment in patients with metastatic pancreatic adenocarcinoma. Last author DOI 10.1016/j.pan.2025.01.012↗
  8. The protective role of anti-parkinsonian drugs in pancreatic cancer risk: A comprehensive case-control study in Taiwan. First author DOI 10.1111/cas.16422↗
  9. Validation of a Prognostic Nomogram for Patients with Metastatic Pancreatic Cancer Treated with Nanoliposomal Irinotecan as Second-Line Therapy. Last author DOI 10.1177/10732748251333040↗
  10. Outcomes of Liposomal Irinotecan With 5-FU and Leucovorin in Patients With Metastatic Pancreatic Cancer and Borderline Performance Status. Last author DOI 10.21873/cdp.10430↗
  11. Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation. Co-author DOI 10.1016/j.bj.2023.100696↗
  12. Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer. Last author DOI 10.1016/j.pan.2024.03.014↗
  13. Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer. Co-author DOI 10.3390/cancers15041008↗
  14. Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovo… Last author DOI 10.1002/jhbp.1128↗
  15. Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter Study. Co-author DOI 10.3389/fonc.2022.800842↗
  16. The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan. Co-author PMID 35530292↗
  17. Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma rec… Last author PMID 36225629↗
  18. The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in patients with metastatic pancreatic duc… Last author PMID 36504882↗
  19. High expression of krüppel-like factor 10 or Smad4 predicts clinical benefit of adjuvant chemoradiotherapy in curatively resected pancreatic adenocarcinoma: Fr… Co-author DOI 10.1016/j.radonc.2021.02.037↗
  20. Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study. Last author DOI 10.1177/17588359211058255↗
  21. External validation of the Besançon nomogram in Asian patients with advanced pancreatic cancer receiving second-line chemotherapy: A multi-institute experience… Last author DOI 10.1016/j.pan.2019.11.001↗
  22. Development and validation of a prognostic nomogram to predict survival in patients with advanced pancreatic cancer receiving second-line palliative chemothera… Last author DOI 10.1111/jgh.14926↗
  23. Effect of S-1 on survival outcomes in 838 patients with advanced pancreatic cancer: A 7-year multicenter observational cohort study in Taiwan. Last author DOI 10.1002/cam4.2094↗
  24. Association of time interval between cancer diagnosis and initiation of palliative chemotherapy with overall survival in patients with unresectable pancreatic … Last author DOI 10.1002/cam4.2254↗
  25. Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy. Last author DOI 10.1002/cam4.2483↗
  26. Evolution of the chemotherapeutic landscape and survival outcome in patients with metastatic pancreatic cancer: a four-institute cohort study in Taiwan, 2010-2… Co-author DOI 10.2147/cmar.s196300↗
  27. Prognostic Factors for Advanced Pancreatic Cancer Treated with Gemcitabine Plus S-1: Retrospective Analysis and Development of a Prognostic Model. Last author DOI 10.3390/cancers11010057↗
  28. Lung Metastases in Patients with Stage IV Pancreatic Cancer: Prevalence, Risk Factors, and Survival Impact. Last author DOI 10.3390/jcm8091402↗
  29. Incidence, Risk Factors, and Outcomes of Arterial Thromboembolism in Patients with Pancreatic Cancer Following Palliative Chemotherapy. Last author DOI 10.3390/cancers10110432↗
  30. Venous Thromboembolism in Asian Patients with Pancreatic Cancer Following Palliative Chemotherapy: Low Incidence but a Negative Prognosticator for Those with E… Last author DOI 10.3390/cancers10120501↗
  31. Concurrent chemoradiotherapy with or without induction chemotherapy versus chemotherapy alone in patients with locally advanced pancreatic cancer. Co-author PMID 25368287↗

Closest collaborators

The 25 strongest of 57 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tai‐Jan Chiu · 15 shared papers, 2021–2026 · strength 2.98
  2. Jen‐Shi Chen · 21 shared papers, 2014–2026 · strength 2.95
  3. Yen‐Yang Chen · 20 shared papers, 2018–2026 · strength 2.66
  4. Li‐Yuan Bai · 12 shared papers, 2021–2026 · strength 1.93
  5. Yung‐Yeh Su · 11 shared papers, 2021–2026 · strength 1.80
  6. Yu‐Shin Hung · 12 shared papers, 2018–2026 · strength 1.76
  7. Chung‐Pin Li · 11 shared papers, 2021–2026 · strength 1.75
  8. Shih‐Hung Yang · 11 shared papers, 2021–2026 · strength 1.75
  9. Nai‐Jung Chiang · 10 shared papers, 2021–2025 · strength 1.43
  10. Li‐Tzong Chen · 10 shared papers, 2021–2025 · strength 1.41
  11. Yan‐Shen Shan · 10 shared papers, 2021–2025 · strength 1.37
  12. Chi-Chen Lan · 3 shared papers, 2025–2026 · strength 1.18
  13. Cheng‐Ming Peng · 8 shared papers, 2021–2024 · strength 1.06
  14. Pei‐Hung Chang · 10 shared papers, 2018–2020 · strength 0.96
  15. Chieh-Ying Chang · 2 shared papers, 2025–2026 · strength 0.62
  16. Hsiu-Tzu Wang · 2 shared papers, 2026 · strength 0.50
  17. I‐Wei Ho · 2 shared papers, 2026 · strength 0.50
  18. Pei‐Wei Huang · 3 shared papers, 2019 · strength 0.28
  19. Hsuan‐Chia Yang · 1 shared paper, 2025 · strength 0.26
  20. Chih‐Wei Huang · 1 shared paper, 2025 · strength 0.26
  21. Jason C. Hsu · 1 shared paper, 2025 · strength 0.26
  22. Keng-Hao Liu · 2 shared papers, 2019–2020 · strength 0.19
  23. Ching‐Fu Chang · 2 shared papers, 2019 · strength 0.19
  24. Hsin‐Chen Lin · 1 shared paper, 2024 · strength 0.19
  25. Chien‐Jui Huang · 1 shared paper, 2024 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.